Get the Stockscreener App
38.91
8.06%
-3.475
Mbx Biosciences Inc stock is traded at $38.91, with a volume of 288.38K.
It is down -8.06% in the last 24 hours and up +21.04% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$42.39
Open:
$42
24h Volume:
288.38K
Relative Volume:
0.36
Market Cap:
$1.75B
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-24.86
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-3.84%
1M Performance:
+21.04%
6M Performance:
+184.90%
1Y Performance:
+232.27%
1-Day Range:
$38.79
$42.56
1-Week Range:
$38.79
$43.98
52-Week Range:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
39.00 | 1.90B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.83 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return - Yahoo Finance
MBX Biosciences appoints Laurie Stelzer to board of directors By Investing.com - Investing.com Nigeria
MBX Biosciences, Inc. Announces Board and Committee Changes - marketscreener.com
MBX Biosciences appoints Laurie Stelzer to board of directors - Investing.com
MBX Biosciences Appoints Laurie Stelzer to Board, Audit Chair - TipRanks
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair - GlobeNewswire
Forecast Cut: Should I buy MBX Biosciences Inc stock nowEarnings Overview Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
MBX Biosciences (NASDAQ:MBX) Shares Down 6.8%Here's What Happened - MarketBeat
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Teladoc (TDOC) and Pfizer (PFE) - The Globe and Mail
Guggenheim raises MBX Biosciences stock price target on obesity drug potential - Investing.com Nigeria
MBX Biosciences Surges Amid Strategic Partnership Developments - timothysykes.com
Breakout Watch: What makes MBX Biosciences Inc stock attractive to growth fundsEarnings Summary Report & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline - Investing.com Canada
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Trading 7.6% HigherTime to Buy? - MarketBeat
MBX Biosciences Sees Shares Surge amid Strategic Partnerships - timothysykes.com
MBX Biosciences Highlights 2026 Outlook and Pipeline Progress - TipRanks
Portfolio Shifts: Is MBX Biosciences Inc stock influenced by commodity pricesJuly 2025 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026 - TradingView — Track All Markets
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
MBX Biosciences (NASDAQ:MBX) Rating Increased to Strong-Buy at UBS Group - MarketBeat
Will MBX Biosciences Inc. stock benefit from upcoming earnings reports2025 Bull vs Bear & Real-Time Buy Zone Alerts - Улправда
Is MBX Biosciences Inc. stock positioned well for digital economyEarnings Growth Summary & High Yield Equity Trading Tips - Улправда
Will MBX Biosciences Inc. stock recover faster than marketJuly 2025 Sector Moves & Real-Time Market Trend Scan - Улправда
MBX Surge: Is It the Right Time? - timothysykes.com
MBX Biosciences (NASDAQ:MBX) Shares Gap UpTime to Buy? - MarketBeat
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Will MBX Biosciences Inc. stock attract ESG investors2026 world cup usa national team third place match star players set piece tactics match prediction tactical review - ulpravda.ru
UBS initiates coverage on MBX Biosciences stock with Buy rating - Investing.com
UBS initiates coverage on MBX Biosciences stock with Buy rating By Investing.com - Investing.com Australia
MBX Biosciences (NASDAQ:MBX) Trading Down 8.4%Here's Why - MarketBeat
Power Grid Corporation of India Limited Forms Bullish Flag Upside AheadGlobal Trade Effects & Free Trading Psychology Coaching - earlytimes.in
Commit To Purchase Mbx Biosciences At $20, Earn 25% Using Options - Nasdaq
MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8%Here's What Happened - MarketBeat
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8%Still a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD - Investing.com
MBX Biosciences price target raised to $50 from $45 at Stifel - MSN
Take Profit: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - moha.gov.vn
MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to NASDAQ Biotechnology Index - marketscreener.com
Dip Buying: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Intraday Action & Stock Portfolio Risk Control - moha.gov.vn
MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen - MarketBeat
How sustainable is MBX Biosciences Inc. stock dividend payoutPortfolio Profit Report & Safe Entry Point Alerts - Улправда
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):